Campbell & CO Investment Adviser LLC Gilead Sciences, Inc. Transaction History

Campbell & CO Investment Adviser LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$71.58 - $87.29 $205,506 - $250,609	-2,871 Reduced 38.61%	4,565 $334,000
Q4 2023 Feb 13, 2024	BUY	$73.27 - $83.09 $87,557 - $99,292	1,195 Added 19.15%	7,436 $602,000
Q3 2023 Nov 08, 2023	BUY	$73.94 - $80.67 $461,459 - $503,461	6,241 New	6,241 $467,000
Q1 2023 May 11, 2023	BUY	$77.31 - $88.08 $595,287 - $678,216	7,700 New	7,700 $638,000
Q4 2020 Feb 09, 2021	SELL	$56.65 - $64.55 $1.4 Million - $1.6 Million	-24,790 Closed	0 $0
Q3 2020 Oct 15, 2020	BUY	$62.1 - $78.08 $1.54 Million - $1.94 Million	24,790 New	24,790 $1.57 Million
Q1 2020 Apr 29, 2020	SELL	$62.63 - $80.22 $677,092 - $867,258	-10,811 Closed	0 $0
Q4 2019 Jan 23, 2020	BUY	$61.62 - $67.78 $389,500 - $428,437	6,321 Added 140.78%	10,811 $702,000
Q3 2019 Oct 16, 2019	BUY	$62.51 - $69.0 $280,669 - $309,810	4,490 New	4,490 $285,000

1,931

991M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.